Abstract
Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Drug Delivery Letters
Title:Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles
Volume: 8 Issue: 3
Author(s): Zahrah Alhalili, Joe Shapter*, Daniela Figueroa and Barbara Sanderson
Affiliation:
- Flinders Centre for NanoScale Science and Technology, School of Chemical and Physical Sciences, Flinders University, Adelaide, SA 5001,Australia
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Abstract: Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Export Options
About this article
Cite this article as:
Alhalili Zahrah, Shapter Joe*, Figueroa Daniela and Sanderson Barbara, Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles, Drug Delivery Letters 2018; 8 (3) . https://dx.doi.org/10.2174/2210303108666180913115509
DOI https://dx.doi.org/10.2174/2210303108666180913115509 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Protein Targets in the Treatment of Cancers (Guest Editor: Sabbir Ahmed)]
Anti-Cancer Agents in Medicinal Chemistry Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Current Cancer Drug Targets Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning
Central Nervous System Agents in Medicinal Chemistry Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry The Global Component-Target Network in Panax Ginseng C
Letters in Drug Design & Discovery Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
Reviews on Recent Clinical Trials Breast Cancer Detection and Classification using Traditional Computer Vision Techniques: A Comprehensive Review
Current Medical Imaging ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis in Mouse Melanoma B16F10 Cells
Recent Patents on Anti-Cancer Drug Discovery Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Current Diabetes Reviews Recent Developments of DNA Poisons - Human DNA Topoisomerase IIα Inhibitors - as Anticancer Agents
Current Pharmaceutical Design Withdrawal Notice: Anti-cancer Effect of Urginea Maritima Bulb Extract In Vitro through Cell Cycle Arrest and Induction of Apoptosis in Human Breast Cancer Cell Lines
Current Drug Discovery Technologies Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut
Current Medicinal Chemistry